The rise of GLP-1 receptor agonists is significantly transforming the landscape of obesity treatment, impacting the growth of bariatric procedures and affecting device sales. Innovations and future reimbursements in the GLP-1 space are expected to continue placing downward pressure on the demand for bariatric procedures. Despite this, the growing obese population and increased treatment rates are anticipated to drive the obesity intervention market. Additionally, less-invasive endoluminal procedures and the adoption of innovative technologies that command higher prices will contribute to sustaining the obesity intervention market.
This Medtech 360 Report provides comprehensive data and analysis on the state of the obesity intervention market in the US from 2019 through 2034.
GLP-1 receptor agonists have been experiencing a meteoric rise in adoption among the US patient population in recent years.
How has the rise in GLP-1 receptor agonist prescriptions affected the obesity intervention market?
Will the obesity intervention market recover from the increasing use of GLP-1 receptor agonists?
Considering the emerging pharmacological therapies in the pipeline, what is the long-term outlook for bariatric surgery procedures?
Can there be a complementary use of GLP-1 receptor agonists and bariatric surgery?
What strategies can competitors within the obesity intervention market employ to adapt to the increasing use of GLP-1 receptor agonists?
Robotic-assisted bariatric procedures will support the overall obesity intervention market.
Which procedure types have the highest and lowest laparoscopic technique penetration amid the growing influence of robotic surgery?
Given the rise of robotic surgery, which laparoscopic bariatric procedures are still growing, and which ones are nearing saturation?
Which technique-open or laparoscopic-is more affected by the rise of robotic surgery?
There is a growing trend among US physicians to adopt novel bariatric procedures for weight loss.
What are these new procedures?
What will be the expected growth rate of these procedures over the forecast period?
New competitors are expected to enter this space within the forecast period.
Who are these competitors and what products are they bringing to the market?
Which segments are seeing the most incoming competitors?
Table of Contents
United States
Abstract
Executive Summary
COVID-19 Updates
Market Highlights
Competitive Highlights
Market Developments
Procedures Covered
Products Covered
Key Report Updates
Obesity Intervention Market
Market Highlights
Key Content Updates
Market Definitions
Epidemiology Forecast Data
Procedure Forecast Data
Market Forecast Data
Market Shares
Competitive Insights
Medtronic
Johnson & Johnson Medtech
Boston Scientific
ReShape Lifesciences
Other Key Competitors
Factors Affecting All Competitors
Market Developments
Gastric Band Market
Market Highlights
Key Content Updates
Market Definitions
Market Forecast Data
Market Shares
Competitive Insights
US Gastric Band Competitive Insights
Internal Closure Device Market
Market Highlights
Key Content Updates
Market Definitions
Market Forecast Data
Market Shares
Competitive Insights
US Internal Closure Device Competitive Insights
Intragastric Balloon Market
Market Highlights
Key Content Updates
Market Definitions
Market Forecast Data
Market Shares
Competitive Insights
US Intragastric Balloon Competitive Insights
Factors Affecting All Competitors
Appendix
Abbreviations
Bibliography
Methodology
Core Country Coverage Methodology
Research Methodology
Marketrack Methodology
PriceTrack Methodology
Forecast Methodology
Supplemental Country Coverage Methodology
Base-Year Ratio Analysis
Market Forecasting
Tables and figures
Obesity Intervention Market, by Product Type, US (USD), 2019-2034
Obesity Intervention Market Landscape, US (USD), 2024 and 2034